Compare VFS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFS | PTGX |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | Vietnam | United States |
| Employees | 17823 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.4B |
| IPO Year | N/A | 2016 |
| Metric | VFS | PTGX |
|---|---|---|
| Price | $3.06 | $110.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $5.83 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 536.9K | 511.9K |
| Earning Date | 06-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | $70.58 | $874.25 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2,215.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $49.86 |
| 52 Week High | $5.29 | $113.66 |
| Indicator | VFS | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 27.30 | 61.70 |
| Support Level | $2.84 | $94.48 |
| Resistance Level | $3.42 | N/A |
| Average True Range (ATR) | 0.14 | 4.91 |
| MACD | -0.00 | 1.40 |
| Stochastic Oscillator | 18.00 | 87.97 |
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Car, E-scooter and Ebus. The Car segment includes the design, development, manufacturing and sales of cars and related battery lease and battery charging services for cars. The E-scooter segment includes the design, development, manufacturing and sales of e-scooters and related battery lease and battery charging service for e-scooters. The Ebus segment includes the design, development, manufacturing and sales of Ebus.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.